Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries
Among patients with RA and PsA initiating a bDMARD, the risk of ILD was higher than in the general population, and was highest in RA. MTX comedication was not a risk determinant for ILD.
Authors
- Eirik Klami Kristianslund (ORCID: https://orcid.org/0000-0002-4963-3285)
- Brigitte Michelsen (ORCID: https://orcid.org/0000-0003-0103-2840)
- Daniela Di Giuseppe (ORCID: https://orcid.org/0000-0003-3817-8288)
- Johan Askling (ORCID: https://orcid.org/0000-0003-0433-0616)
- Tore Kristian Kvien (ORCID: https://orcid.org/0000-0002-8441-3093)
- Till Uhlig (ORCID: https://orcid.org/0000-0002-6881-9552)
- Gudrun Reynisdottir
- Kalle Aaltonen (ORCID: https://orcid.org/0000-0002-5650-203X)
- Þórarinn Jónmundsson (ORCID: https://orcid.org/0000-0001-9158-0087)
- Björn Guðbjörnsson (ORCID: https://orcid.org/0000-0003-4631-6505)
- Merete Lund Hetland (ORCID: https://orcid.org/0000-0003-4229-6818)
- Heikki Relas (ORCID: https://orcid.org/0000-0001-8065-3930)
- Bente Glintborg (ORCID: https://orcid.org/0000-0002-8931-8482)
- Sella Aarrestad Provan (ORCID: https://orcid.org/0000-0001-5442-902X)
- Lotta Ljung (ORCID: https://orcid.org/0000-0001-8999-0925)
- Joe Sexton (ORCID: https://orcid.org/0000-0003-4717-9637)
Institutions
- Reykjavík University (IS)
- Karolinska University Hospital (SE)
- University of Helsinki (FI)
- University of Iceland (IS)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- National University Hospital of Iceland (IS)
- University of Inland Norway (NO)
- Diakonhjemmet Hospital (NO)
- Ministry of Social Affairs and Health (FI)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.3899/jrheum.2024-0252
- Citations
- 7
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Innovationsfonden
- Celltrion
- Bundesministerium für Bildung und Forschung
- Vetenskapsrådet
- NordForsk
- Norges Forskningsråd
- Swedish Orphan Biovitrum